Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to (1) evaluate the bioequivalence(BE) of GLA5PR
GLARS-NF3 tablet 300mg administered regular diet relative to GLA5PR GLARS-NF1 tablet 300mg
administered regular diet and (2) determine the safety and tolerability of a single dose of
GLA5PR GLARS-NF3 tablet 300mg administered regular diet and GLA5PR GLARS-NF1 tablet 300mg
administered regular diet.